Portfolio company
MyoGene Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This company develops gene-editing therapies to treat patients with Duchenne muscular dystrophy by restoring production of the dystrophin protein.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
MyoGene Bio
This company develops gene-editing therapies to treat Duchenne muscular dystrophy and other muscle-wasting diseases for patients worldwide.
Exonics
This company develops gene editing therapies for patients with Duchenne muscular dystrophy and other severe genetic neuromuscular diseases.
MyoPax
This company develops muscle regeneration cell and gene therapies for patients with congenital malformations, trauma, hereditary dystrophies and muscle wasting disorders.
Exonics Therapeutics
The company develops gene editing therapies for patients with Duchenne muscular dystrophy and other genetic neuromuscular diseases.
Myosana Therapeutics, Inc.
This company develops non-viral gene therapies for patients with cardiac and neuromuscular diseases, including Duchenne muscular dystrophy and X-linked myotubular myopathy.
Bamboo Therapeutics
This company develops gene therapies for patients with rare neuromuscular and central nervous system diseases, including Duchenne muscular dystrophy.
Satellos Bioscience
This company develops oral small molecule drugs to restore muscle regeneration for patients with Duchenne muscular dystrophy and other degenerative muscle diseases.
Capricor
This biotechnology company develops cell and exosome-based therapies to treat Duchenne muscular dystrophy and other serious diseases for patients.